A novel immunotherapy for relapsed/refractory acute lymphoblastic leukemia (ALL)

被引：0
|
作者：
Saini, Uksha
Hixon, Julie
Rodrigues, Gisele
Foley, Christopher
Chibas, Leniher Castan
Hamilton, Ross
Li, Wenqing
Schafer, Eric S.
Rheingold, Susan
Heffernan, Michael
Breitfeld, Philip
Durum, Scott
Varadhachary, Atul
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-5664
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5664
引用
下载
收藏
页数：3
相关论文
共 50 条
  • [31] Phase II study of liposomal vincristine (lipoV) in relapsed or refractory adult acute lymphoblastic leukemia (ALL).
    Thomas, DA
    Sarris, A
    O'Brien, S
    Cortes, J
    Giles, FJ
    Faderl, S
    Keating, MJ
    Burge, C
    Cabanillas, F
    Kantarjian, H
    BLOOD, 1999, 94 (10) : 238B - 238B
  • [32] Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia
    Badar, Talha
    Szabo, Aniko
    Dinner, Shira
    Liedtke, Michaela
    Burkart, Madelyn
    Shallis, Rory M.
    Yurkiewicz, Ilana R.
    Kuo, Eric
    Khan, Muhammad Ali
    Balasubramanian, Suresh
    Yang, Jay
    Hefazi, Mehrdad
    Podoltsev, Nikolai
    Patel, Anand
    Curran, Emily
    Wang, Amy
    Arslan, Shukaib
    Aldoss, Ibrahim
    Siebenaller, Caitlin
    Mattison, Ryan J.
    Litzow, Mark R.
    Wadleigh, Martha
    Advani, Anjali S.
    Atallah, Ehab
    CANCER, 2021, 127 (07) : 1039 - 1048
  • [33] Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia
    Ganzel, Chezi
    Kharit, Mira
    Duksin, Chen
    Rowe, Jacob M.
    HAEMATOLOGICA, 2018, 103 (10) : E489 - E490
  • [34] Bortezomib Combined Chemotherapy for Children with Relapsed/refractory Acute Lymphoblastic Leukemia
    Sakaguchi, Hirotoshi
    Maemura, Ryo
    Yamamori, Ayako
    Wakamatsu, Manabu
    Yoshida, Nao
    Kato, Koji
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S89 - S90
  • [35] Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomibbased chemotherapy
    Zhao, Junmei
    Wang, Chao
    Song, Yongping
    Liu, Yuzhang
    Fang, Baijun
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2015, 8 : 211 - 214
  • [36] Trial initiated for liposomal vincristine in relapsed/refractory acute lymphoblastic leukemia
    不详
    ONCOLOGY-NEW YORK, 2006, 20 (10): : 1292 - 1292
  • [37] Modeling Relapsed, Refractory Acute Lymphoblastic Leukemia from a Child with Neurofibromatosis
    Heatley, Susan L.
    Page, Elyse C.
    Eadie, Laura N.
    McClure, Barbara J.
    Rehn, Jacqueline
    Yeung, David T.
    Osborn, Michael Philip
    Revesz, Tamas
    Kirby, Maria
    White, Deborah L.
    BLOOD, 2021, 138
  • [38] Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia
    George, Binsah
    Kantarjian, Hagop
    Jabbour, Elias
    Jain, Nitin
    IMMUNOTHERAPY, 2016, 8 (02) : 135 - 143
  • [39] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
    Deepa Bhojwani
    Richard Sposto
    Nirali N. Shah
    Vilmarie Rodriguez
    Constance Yuan
    Maryalice Stetler-Stevenson
    Maureen M. O’Brien
    Jennifer L. McNeer
    Amrana Quereshi
    Aurelie Cabannes
    Paul Schlegel
    Claudia Rossig
    Luciano Dalla-Pozza
    Keith August
    Sarah Alexander
    Jean-Pierre Bourquin
    Michel Zwaan
    Elizabeth A. Raetz
    Mignon L. Loh
    Susan R. Rheingold
    Leukemia, 2019, 33 : 884 - 892
  • [40] Efficacy and Toxicity of Inotuzumab in a Patient with Relapsed/ Refractory Acute Lymphoblastic Leukemia
    Giagnuolo, G.
    Petruzziello, F.
    Maisto, G.
    D'Amico, M. R.
    Ripaldi, M.
    Loffredo, G.
    Buffardi, S.
    Menna, G.
    Parasole, R.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S176 - S176
12345